X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-03 | NVCR | Weinberg Uri | Chief Innovation Officer | S - Sale | $18.92 | -268 | 166,243 | 0% | -$5,071 | ||||||
2025-03-03 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $18.54 | -2,527 | 143,673 | -2% | -$46,841 | ||||||
2025-03-03 | NVCR | Cordova Ashley | CEO | S - Sale | $18.54 | -2,053 | 204,005 | -1% | -$38,055 | ||||||
2025-03-03 | NVCR | Paravasthu Mukund | COO | S - Sale | $18.54 | -250 | 29,173 | -1% | -$4,634 | ||||||
| A | 2025-02-28 | NVCR | Weinberg Uri | Chief Innovation Officer | S - Sale | $18.75 | -4,637 | 166,511 | -3% | -$86,949 | |||||
| AM | 2025-02-27 | NVCR | Cordova Ashley | CEO | S - Sale | $19.72 | -13,494 | 206,058 | -6% | -$266,126 | |||||
| AM | 2025-02-27 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $19.70 | -15,036 | 146,200 | -9% | -$296,257 | |||||
| A | 2025-02-27 | NVCR | Puri Michal Nath | CHRO | S - Sale | $20.02 | -1,387 | 108,706 | -1% | -$27,773 | |||||
| A | 2025-02-27 | NVCR | Leupin Nicolas | Chief Medical Officer | S - Sale | $20.02 | -991 | 50,133 | -2% | -$19,844 | |||||
| AM | 2025-02-27 | NVCR | Paravasthu Mukund | COO | S - Sale | $19.71 | -2,014 | 29,423 | -6% | -$39,688 | |||||
2025-02-28 | NVCR | Weinberg Uri | Chief Innovation Officer | S - Sale | $18.75 | -4,637 | 166,511 | -3% | -$86,949 | ||||||
2025-02-27 | NVCR | Leupin Nicolas | Chief Medical Officer | S - Sale | $20.02 | -991 | 50,133 | -2% | -$19,844 | ||||||
2025-02-27 | NVCR | Puri Michal Nath | CHRO | S - Sale | $20.02 | -1,387 | 108,706 | -1% | -$27,773 | ||||||
| M | 2025-02-27 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $19.70 | -15,036 | 146,200 | -9% | -$296,257 | |||||
| M | 2025-02-27 | NVCR | Cordova Ashley | CEO | S - Sale | $19.72 | -13,494 | 206,058 | -6% | -$266,126 | |||||
| M | 2025-02-27 | NVCR | Paravasthu Mukund | COO | S - Sale | $19.71 | -2,014 | 29,423 | -6% | -$39,688 | |||||
2025-01-11 | NVCR | Paravasthu Mukund | COO | S - Sale | $26.81 | -2,160 | 31,437 | -6% | -$57,906 | ||||||
| D | 2024-11-02 | NVCR | Paravasthu Mukund | COO | S - Sale+OE | $16.69 | -44 | 33,597 | 0% | -$734 | |||||
2024-10-31 | NVCR | Puri Michal Nath | CHRO | S - Sale | $15.79 | -810 | 110,093 | -1% | -$12,792 | ||||||
2024-11-01 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $15.94 | -598 | 161,236 | 0% | -$9,531 | ||||||
2024-11-01 | NVCR | Paravasthu Mukund | COO | S - Sale | $15.88 | -160 | 3,503 | -4% | -$2,540 | ||||||
2024-08-02 | NVCR | Cordova Ashley | CFO | S - Sale | $20.14 | -688 | 219,179 | 0% | -$13,857 | ||||||
| D | 2024-06-04 | NVCR | Vernon W Anthony | Dir | S - Sale+OE | $23.89 | -964 | 334,683 | 0% | -$23,033 | |||||
| D | 2024-06-04 | NVCR | Scannell Timothy J | Dir | S - Sale+OE | $23.89 | -964 | 10,945 | -8% | -$23,027 | |||||
| D | 2024-06-04 | NVCR | Leung Gabriel | Dir | S - Sale+OE | $23.89 | -964 | 161,367 | -1% | -$23,025 | |||||
| M | 2024-03-01 | NVCR | Groenhuysen Wilhelmus Cm | COO | S - Sale | $16.02 | -3,324 | 251,235 | -1% | -$53,253 | |||||
| M | 2024-03-01 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $16.02 | -2,519 | 160,098 | -2% | -$40,358 | |||||
| D | 2024-02-28 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale+OE | $16.14 | -2,078 | 162,617 | -1% | -$33,545 | |||||
| D | 2024-02-28 | NVCR | Groenhuysen Wilhelmus Cm | COO | S - Sale+OE | $16.14 | -2,303 | 254,559 | -1% | -$37,177 | |||||
2023-11-07 | NVCR | Shah Pritesh | Chief Growth Officer | S - Sale | $12.65 | -382 | 124,511 | 0% | -$4,832 | ||||||
2023-09-01 | NVCR | Cordova Ashley | CFO | S - Sale | $21.82 | -883 | 99,650 | -1% | -$19,265 | ||||||
2023-09-01 | NVCR | Groenhuysen Wilhelmus Cm | COO | S - Sale | $21.82 | -294 | 209,825 | 0% | -$6,414 | ||||||
2023-09-01 | NVCR | Shah Pritesh | Chief Growth Officer | S - Sale | $21.82 | -273 | 124,893 | 0% | -$5,956 | ||||||
2023-08-02 | NVCR | Cordova Ashley | CFO | S - Sale | $30.25 | -1,144 | 100,533 | -1% | -$34,607 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |